Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actelion Pharmaceutical
Reports from Switzerland, Japan and the United States add new data to diabetes research
June 23rd, 2006
Data on diabetes are outlined in reports from Switzerland, Japan and the United States. Study 1: The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. According to a study from Switzerland, "Urotensin-II (U-II) is a cyclic peptide that acts through a specific G-protein-coupled receptor, UT receptor. Urotensin-II and UT receptors have been described in pancreas and kidney, but their function is not well understood. We studied the effects of chronic treatment of diabetic rats with the orally active selective U-II receptor antagonist palosuran." "Streptozotocin treatment causes...
Source: Biotech Law Weekly (2006-06-23)
|
